First drug approved for treatment of spinal muscular atrophy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Spinraza (nusinersen), the first drug to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

SMA is a genetic disease that causes weakness and muscle wasting because of the loss of lower motor neurons controlling movement. SMA is classified in many types based on age of onset, severity of muscle weakness and symptoms. Spinraza is an injection administered into the fluid surrounding the spinal cord, approved for use across the range of spinal muscular atrophy patients.

The efficacy of Spinraza was demonstrated in a clinical trial including 121 patients (aged < 7 mo at the time of 1st dose) with infantile-onset SMA diagnosed before 6 months of age. Patients were randomized to receive an injection of Spinraza, into the fluid surrounding the spinal cord, or undergo a mock procedure without drug injection (a skin prick). In an interim analysis 40% of patients treated with Spinraza achieved improvement in motor milestones (head control, sitting, ability to kick in supine position, rolling, crawling, standing and walking), whereas none of the control patients did.

The findings of additional open-label uncontrolled clinical studies conducted in symptomatic patients (aged 30 days to 15 yrs at the time of 1st dose) and presymptomatic patients (aged 8 days to 42 days at the time of 1st dose) support the clinical efficacy demonstrated in the controlled clinical trial in infantile-onset patients.

The most common side effects reported in patients...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert - Absorb GT1 Bioresorbable Vascular Scaffold associated with increased risk of CV events

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Safety Alert: breast implants associated with risk of developing anaplastic large cell lymphoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Odactra for house dust mite allergies

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of SynchroMed Implantable Infusion Pump by Medtronic due to hindered drug delivery during priming bolus procedure

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Siliq (brodalumab) for psoriasis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Parsabiv (etelcalcetide) for hyperparathyroidism in dialysis patients

Read more
  • FDA Drug Updates
  • 1 comment

FDA approval of Emflaza (deflazacort) for duchenne muscular dystrophy

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of herbal and dietary supplements by Regeneca – Not manufactured in compliance with GMPs

Read more
  • MedWatch Drug Updates
  • 1 comment

Warning against the use of static preservation solution due to potential contamination with bacteria

Read more
  • MedWatch Drug Updates
  • 1 comment

Safety alert against use of balloon angioplasty devices to treat autonomic dysfunction

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Trulance (plecanatide) for chronic idiopathic constipation

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Edex (alprostadil injection) 10 mcg by Endo Pharmaceuticals - Lack of sterility assurance

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of unexpired sterile injectable labelled “Latex Free” by Advanced Pharma as it may contain synthetic/natural latex

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of XtraHRD Natural Male Enhancement Capsules by Organic Herbal Supply - Contains undeclared drug ingredients

Read more
  • FDA Drug Updates
  • 1 comment

First drug approved for treatment of spinal muscular atrophy

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rubraca (rucaparib) for BRCA+ advanced ovarian cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Eucrisa (crisaborole) for atopic dermatitis

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Human chorionic gonadotropin freeze dried vials by Synergy Rx – Lack of sterility assurance

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Tecentriq (atezolizumab) for treatment of urothelial carcinoma

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Alaris Syringe Pump Module by CareFusion – Faulty sensor may generate false alarm

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Ibuprofen lysine injection, 20 mg /2 mL by Exela Pharma Sciences – Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Well Balance Xanthium & Siler Combo dietary supplement by Kingsway - Contains banned ephedra alkaloids

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xultophy 100/3.6 (insulin degludec and liraglutide injection)

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Soliqua 100/33 (insulin glargine and lixisenatide) for type II diabetes

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Dialog+ Hemodialysis System by B. Braun Medical due to defective conductivity sensors

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of FindrWIRZ Guidewire System by SentreHeart – Possible separation of polytetrafluoroethylene coating

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nuplazid (pimavanserin) for Parkinson’s disease psychosis

Read more